Haleon (NYSE:HLN) Stock Rating Lowered by Rothschild & Co Redburn

Haleon (NYSE:HLN) was downgraded by equities research analysts at Rothschild & Co Redburn from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the stock. Argus raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Haleon Stock Up 0.2%

Haleon stock opened at $9.09 on Tuesday. The stock’s 50 day moving average price is $9.31 and its 200 day moving average price is $9.90. Haleon has a 1-year low of $8.65 and a 1-year high of $11.28. The company has a market cap of $40.20 billion, a PE ratio of 23.30, a price-to-earnings-growth ratio of 2.07 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71.

Haleon (NYSE:HLN) last released its quarterly earnings data on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The business had revenue of $3.65 billion during the quarter. On average, sell-side analysts predict that Haleon will post 0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HLN. Norges Bank purchased a new position in Haleon during the 4th quarter valued at about $163,529,000. Natixis Advisors LLC grew its position in shares of Haleon by 429.8% in the fourth quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after purchasing an additional 8,115,633 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Haleon by 4,315.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock worth $81,155,000 after purchasing an additional 7,845,391 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Haleon by 454.1% during the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock worth $85,940,000 after purchasing an additional 6,966,416 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.